Drug Profile
Antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent
Alternative Names: ANA-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Anti-nuclear antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Doxorubicin liposomal - NanoSmart/NanoValentLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator NanoSmart Pharmaceuticals; NanoValent Pharmaceuticals
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Immunoconjugates; Small molecules
- Mechanism of Action CD antigen inhibitors; DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Ewing's sarcoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 Dec 2019 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA
- 28 Dec 2019 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA